Stock Watch: The Competition Has It
An Existing Standard Of Care Provides A High Barrier To Late-Comers
Executive Summary
Apart from assuming that its new drug will always be a blockbuster, the other common mistake made by biotech companies and investors is that there will invariably be a viable market for its drug. The competition will have other ideas.
You may also be interested in...
Stock Watch: Amarin And Esperion Cut Sales And Marketing Costs
Unlike big pharma, some small commercial companies cut sales and marketing costs in 2021. But with a little imagination, it could go further.
Stock Watch: One Acquisition Does Not Make A Biotech M&A Boom
Another blow-out quarter from Pfizer provided the impetus for an acquisition. But the history of recent commercial-stage biotech transactions and the risky nature of all early-stage companies suggest that the floodgates will not burst open.
Stock Watch: Big Pharma Earnings Season Gets Messy
A post-pandemic rebound in oncology sales contrasts with the lagging revenues of drugs administered by primary care and office-based specialists. Declining COVID-19 vaccine, diagnostic and treatment revenues could add further volatility.